Key facts
- Novai’s last known valuation is $19.8M (Dec 2024).
- It has raised $7.6M.
- Notable investors include Innovate UK, SFC Capital, SyndicateRoom, The FSE Group, Ascension — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Novai
- ·The full record, as it builds
Funding rounds
No funding rounds for Novai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novai
Developer of retinal imaging technology designed to enable early detection and management of eye and brain diseases. The company offers a proprietary biologic combined with advanced image analysis to provide real-time, single-cell insights into retinal cell stress and death, enabling healthcare providers to predict disease activity earlier and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Reading, United Kingdom
- Founded
- 2020
- Employees
- 20
- Website
- novai.co.uk/
- Ownership
- Privately Held (backing)
Novai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novai in its N-PORT filings yet. We sweep new filings monthly.